Search Results - "Falavigna M"

This result is not displayed to guests.
Login for full access.

PCR195 Assessing Time Trade-Off Utilities in Health States of Chronic Rhinosinusitis with Nasal Polyps: A Pilot Study in Brazil.

Authors: Falavigna, M Marmett, B Schneider, NB et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS332-S332. 1p.

CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System.

Authors: Falavigna, M. Watanabe, S.F. Santoro, J. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS33-S33. 1p.

CO65 Modelled Impact of Nirsevimab for All Infants in the Prevention of Respiratory Syncytial Virus (RSV): Related Hospitalizations and Its Predicted Cost to the Brazilian Public Healthcare System.

Authors: Falavigna, M. Watanabe, S.F. Santoro, J. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 12, pS26-S26. 1p.

EE574 Innovative Mechanisms of Pre-Market Authorization Access for Rare Diseases in Brazil. a Case Study of Pabinafusp-Alfa for Mucopolysaccharidosis Type II.

Authors: Tanaka, E. Falavigna, M. Romcy, M.H. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 6, pS164-S164. 1p.

EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries.

Authors: Falavigna, M Deyneli, O Seyam, A et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS63-S63. 1p.

HTA161 Systematic Review With Indirect Comparison of Efficacy and Safety of Dupilumab Versus Omalizumab for Severe Asthma With Allergic Phenotype.

Authors: Barbosa, A Magro, F Buttelli, GBM et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS385-S385. 1p.

EE820 Cost-Utility Analysis of an All-Preterm Infant Immunization With Nirsevimab Against Respiratory Syncytial Virus (RSV): Associated Disease at the Brazilian Private Healthcare System.

Authors: Watanabe, SF Santoro, J Tolardo, A et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 12, pS216-S216. 1p.

HTA26 Economic Evaluation Submitted for Reimbursement in the Brazilian Unified Health System: A Meta-Epidemiological Study.

Authors: Dorneles, G Araujo CLP, de Stein, C et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS249-S249. 1p.

HTA21 Organizations Responsible for the Evaluation of Health Technologies Globally: A Scoping Review.

Authors: Migliavaca C, Borges Colpani, V Marcolino, M et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS248-S248. 1p.

HTA4 Criteria for Decision Making in Health Economic Evaluations: An Analysis of Global Practices.

Authors: Borges, Migliavaca C Colpani, V Marcolino, M et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS244-S244. 1p.

HPR17 Exploring Financing Models for CAR-T Cell Therapies in Global Healthcare Systems: A Comprehensive Scoping Review.

Authors: de Araujo, CLP Schneider, NB Dorneles, G et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS198-S198. 1p.

EE227 Development of a Tool for Quality Assessment of Health Economic Evaluations.

Authors: Borges, Migliavaca C Escher, GN Schneider, NB et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS98-S98. 1p.

EE167 Cost-Effectiveness Evaluations of CAR-T Cell Therapies By Health Technology Assessment Agencies.

Authors: Dorneles, G de Araujo, CLP Schneider, NB et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS88-S88. 1p.

EE129 Tools for the Critical Appraisal of Health Economic Analyses: A Scoping Review.

Authors: Borges, Migliavaca C Escher, GN Dalmas, Graf D et al.

Source: Value in Health. 2024 Supplement, Vol. 27 Issue 6, pS81-S81. 1p.

CO82 Dupilumab Is Effective in Patients with Atopic Dermatitis and Inadequate Response, Intolerance, or Contraindication to Cyclosporine: A Systematic Review and Meta-Analysis.

Authors: Magro, F.J.B. Oldani, P.A. Vieira Duarte, G. et al.

Source: Value in Health. 2023 Supplement, Vol. 26 Issue 6, pS29-S29. 1p.

PRO6 Characteristics of Late Onset Pompe Disease Patients in Latin America - a Patient Registry Analysis.

Authors: Marcondes, B. Wilker, E. Laredo, F. et al.

Source: Value in Health. 2020 Supplement 2, Vol. 23, pS690-S691. 2p.

EE554 Costs Comparison Between Dupilumab and Omalizumab in the Treatment of Severe Allergic Asthma in the Brazilian Private Healthcare Perspective.

Authors: Barbosa, A Magro, FJB Taminato, A et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS164-S164. 1p.

EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective.

Authors: Taminato, A Barbosa, A Magro, FJB et al.

Source: Value in Health. 2022 Suppl, Vol. 25 Issue 12, pS54-S54. 1p.

Cephalic Duodenopancreatectomy in the Treatment of a Bleeding Duodenal Ulcer in a Pancreas Recipient: A Case Report

Authors: Pires, I.S.S. Morais de Siqueira, R. Kroth, L.V. et al.

Source: Transplantation Proceedings. Mar2010, Vol. 42 Issue 2, p594-596. 3p.